Your browser doesn't support javascript.
Convergent antibody responses to SARS-CoV-2 in convalescent individuals.
Robbiani, Davide F; Gaebler, Christian; Muecksch, Frauke; Lorenzi, Julio C C; Wang, Zijun; Cho, Alice; Agudelo, Marianna; Barnes, Christopher O; Gazumyan, Anna; Finkin, Shlomo; Hägglöf, Thomas; Oliveira, Thiago Y; Viant, Charlotte; Hurley, Arlene; Hoffmann, Hans-Heinrich; Millard, Katrina G; Kost, Rhonda G; Cipolla, Melissa; Gordon, Kristie; Bianchini, Filippo; Chen, Spencer T; Ramos, Victor; Patel, Roshni; Dizon, Juan; Shimeliovich, Irina; Mendoza, Pilar; Hartweger, Harald; Nogueira, Lilian; Pack, Maggi; Horowitz, Jill; Schmidt, Fabian; Weisblum, Yiska; Michailidis, Eleftherios; Ashbrook, Alison W; Waltari, Eric; Pak, John E; Huey-Tubman, Kathryn E; Koranda, Nicholas; Hoffman, Pauline R; West, Anthony P; Rice, Charles M; Hatziioannou, Theodora; Bjorkman, Pamela J; Bieniasz, Paul D; Caskey, Marina; Nussenzweig, Michel C.
  • Robbiani DF; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA. drobbiani@irb.usi.ch.
  • Gaebler C; Institute for Research in Biomedicine, Università della Svizzera italiana, Bellinzona, Switzerland. drobbiani@irb.usi.ch.
  • Muecksch F; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Lorenzi JCC; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Wang Z; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Cho A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Agudelo M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Barnes CO; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Gazumyan A; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Finkin S; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Hägglöf T; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Oliveira TY; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Viant C; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Hurley A; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Hoffmann HH; Hospital Program Direction, The Rockefeller University, New York, NY, USA.
  • Millard KG; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Kost RG; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Cipolla M; Center for Clinical Translational Science, The Rockefeller University, New York, NY, USA.
  • Gordon K; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Bianchini F; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Chen ST; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Ramos V; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Patel R; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Dizon J; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Shimeliovich I; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Mendoza P; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Hartweger H; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Nogueira L; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Pack M; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Horowitz J; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Schmidt F; Laboratory of Molecular Immunology, The Rockefeller University, New York, NY, USA.
  • Weisblum Y; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Michailidis E; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Ashbrook AW; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Waltari E; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Pak JE; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Huey-Tubman KE; Chan Zuckerberg Biohub, San Francisco, CA, USA.
  • Koranda N; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Hoffman PR; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • West AP; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Rice CM; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA.
  • Hatziioannou T; Laboratory of Virology and Infectious Disease, The Rockefeller University, New York, NY, USA.
  • Bjorkman PJ; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA.
  • Bieniasz PD; Division of Biology and Biological Engineering, California Institute of Technology, Pasadena, CA, USA. bjorkman@caltech.edu.
  • Caskey M; Laboratory of Retrovirology, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.
  • Nussenzweig MC; Howard Hughes Medical Institute, The Rockefeller University, New York, NY, USA. pbieniasz@rockefeller.edu.
Nature ; 584(7821): 437-442, 2020 08.
Article in English | MEDLINE | ID: covidwho-606946
ABSTRACT
During the coronavirus disease-2019 (COVID-19) pandemic, severe acute respiratory syndrome-related coronavirus-2 (SARS-CoV-2) has led to the infection of millions of people and has claimed hundreds of thousands of lives. The entry of the virus into cells depends on the receptor-binding domain (RBD) of the spike (S) protein of SARS-CoV-2. Although there is currently no vaccine, it is likely that antibodies will be essential for protection. However, little is known about the human antibody response to SARS-CoV-21-5. Here we report on 149 COVID-19-convalescent individuals. Plasma samples collected an average of 39 days after the onset of symptoms had variable half-maximal pseudovirus neutralizing titres; titres were less than 50 in 33% of samples, below 1,000 in 79% of samples and only 1% of samples had titres above 5,000. Antibody sequencing revealed the expansion of clones of RBD-specific memory B cells that expressed closely related antibodies in different individuals. Despite low plasma titres, antibodies to three distinct epitopes on the RBD neutralized the virus with half-maximal inhibitory concentrations (IC50 values) as low as 2 ng ml-1. In conclusion, most convalescent plasma samples obtained from individuals who recover from COVID-19 do not contain high levels of neutralizing activity. Nevertheless, rare but recurring RBD-specific antibodies with potent antiviral activity were found in all individuals tested, suggesting that a vaccine designed to elicit such antibodies could be broadly effective.
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Betacoronavirus / Antibodies, Viral Topics: Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Nature Year: 2020 Document Type: Article Affiliation country: S41586-020-2456-9

Similar

MEDLINE
LILACS
LIS
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: Pneumonia, Viral / Coronavirus Infections / Antibodies, Neutralizing / Betacoronavirus / Antibodies, Viral Topics: Vaccines Limits: Adolescent / Adult / Aged / Female / Humans / Male / Middle aged / Young adult Language: English Journal: Nature Year: 2020 Document Type: Article Affiliation country: S41586-020-2456-9